Plain-English translation of NCT01222260 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our AL amyloidosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested combined with in patients whose light-chain amyloidosis (a serious protein buildup disease) came back after their first treatment. The trial was completed and examined whether this medication combination could help patients who were no longer responding to or had relapsed from earlier therapies.
Patients whose amyloidosis returns after initial melphalan-based treatment often have few good options for second-line therapy. This medication combination was being studied because it showed promise in treating similar blood cancers, and researchers hoped it would also work well for this protein disorder.
Participants in this trial received and as their treatment regimen. Based on the trial design, participants would have attended study visits for clinical monitoring, blood work, and assessment of how well the treatment was working and whether they experienced any side effects. The exact visit schedule and duration would have been determined by the research team at Columbia University.
AI-generated summary from trial data · Sep 21, 2026 · Not medical advice
United States